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Abstract

The fibrotic diseases encompass a wide spectrum of entities including such multisystemic
diseases as systemic sclerosis, nephrogenic systemic fibrosis and sclerodermatous graft versus
host disease, as well as organ-specific disorders such as pulmonary, liver, and kidney fibrosis.
Collectively, given the wide variety of affected organs, the chronic nature of the fibrotic
processes, and the large number of individuals suffering their devastating effects, these diseases
pose one of the most serious health problems in current medicine and a serious economic burden
to society. Despite these considerations there is currently no accepted effective treatment.
However, remarkable progress has been achieved in the elucidation of their pathogenesis
including the identification of the critical role of myofibroblasts and the determination of
molecular mechanisms that result in the transcriptional activation of the genes responsible for the
fibrotic process. Here we review the origin of the myofibroblast and discuss the crucial
regulatory pathways involving multiple growth factors and cytokines that participate in the
pathogenesis of the fibrotic process. Potentially effective therapeutic strategies based upon this
new information are considered in detail and the major challenges that remain and their possible
solutions are presented. It is expected that translational efforts devoted to convert this new
knowledge into novel and effective antifibrotic drugs will be forthcoming in the near future.

Keywords: Fibrotic Diseases, Myofibroblast, Fibrosis, Tyrosine Kinases, TGF-ß, Antifibrotic
Therapy
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The Problem

Fibrotic diseases encompass a wide spectrum of entities including such multisystemic
diseases as systemic sclerosis (SSc), sclerodermatous graft versus host disease, and nephrogenic
systemic fibrosis, as well as organ-specific disorders such as pulmonary, liver, and kidney
fibrosis (1-8). Although their etiology and causative mechanisms vary widely, these conditions
share the common feature of elevated expression of genes encoding matrix proteins, and the
resulting fibrosis disrupts the normal architecture of the affected organs, ultimately leading to
their dysfunction and failure (9-11). Indeed, it is the persistent production of extracellular matrix
(ECM) macromolecules by activated mesenchymal cells, known as myofibroblasts, that
distinguishes controlled repair occurring during normal wound healing from the uncontrolled
fibrosis that is the hallmark of fibrotic diseases.
Collectively, given the wide variety of affected organs, the chronic nature of the fibrotic
processes, and the large number of individuals suffering their devastating effects, these diseases
pose one of the most serious health problems in current medicine and represent an enormous
challenge to health services, and a serious economic burden to society. It has been estimated that
as much as 45% of the mortality in the Western developed countries is now caused by fibrotic
diseases (11) and the mortality in underdeveloped or developing countries caused by these
diseases is likely to be even much higher. Despite these considerations there is currently no
accepted effective treatment.

However, recent identification of the critical role of the

myofibroblast and elucidation of crucial regulatory pathways resulting in the transcriptional
activation of the genes encoding collagens and other proteins responsible for the fibrotic process
has been of substantial importance and has provided a sound basis for the development of novel
and effective means of therapy. Unfortunately, the current lack of approved drugs for treatment
3

of these diseases indicates that recent knowledge has not yet been translated into effective
therapies, however, it can be expected that this situation will be reversed in the near future.
Origin and Critical Role of Activated Fibroblasts/Myofibroblasts in Fibrotic Tissues
Although the causative agent or initiating event of the fibrotic disorders are quite diverse, and
their pathogenesis is variable, a common feature in affected tissues is the presence of large
numbers of activated fibroblasts or myofibroblasts. These cells display unique biological
functions, including increased production of fibrillar type I and type III collagens, expression of
α-smooth muscle actin (α-SMA), a molecular marker of activated myofibroblasts, and reduction
in the expression of genes encoding ECM–degradative enzymes (12-15). Regardless of the
etiological event, the accumulation of myofibroblasts in affected tissues and the uncontrolled
persistence of their elevated biosynthetic functions are crucial determinants of the extent and rate
of progression of the fibrotic diseases, and of their clinical course, response to therapy,
prognosis, and mortality (9).
The origins of myofibroblasts are diverse and may differ depending on the affected organ
and the initiating event. There are four important sources of the myofibroblasts encountered in
the fibrotic tissues as illustrated in Figure 1: i) Proliferation and activation of tissue resident
fibroblasts or perivascular and vascular adventitial fibroblasts in response to specific signals
from infiltrating inflammatory cells resulting in activation of quiescent fibroblasts to a
myofibroblast phenotype (16). ii) Recruitment of fibroblast precursor cells from bone marrow
through local release of activated chemokines. These circulating bone marrow precursor cells are
known as fibrocytes, a unique cell population expressing bone marrow cellular surface markers,
such as CD34 protein, but capable of ECM production. These cells can migrate from the
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bloodstream in response to specific chemokine gradients and localize in tissues undergoing
pathological fibrogenesis (17-18). iii) Transdifferentiation of epithelial cells to myofibroblasts, a
process known as epithelial to mesenchymal transition (EMT), which is induced by transforming
growth factor β (TGF-β) and perhaps other polypeptides such as endothelin-1 (ET-1) or insulin
growth factor (19-21). In EMT, epithelial cells lose their epithelial characteristics, including Ecadherin expression and apical-basal polarity, and reorganize their cytoskeleton to acquire a
motile behavior and the phenotype of myofibroblasts including the expression of α-SMA and
fibroblast-specific proteins such as type I collagen. Although some recent studies employing
genetic cell lineage tracing studies have raised controversy (22), numerous publications have
described the occurrence of EMT in the course of renal, pulmonary, and liver fibrosis (21,23-25).
iv) Another type of cellular transition similar to EMT, but in which endothelial cells undergo a
mesenchymal transition (EndoMT) has emerged as a possible mechanism in pathological fibrosis
(26,27). During EndoMT endothelial cells lose their specific endothelial cell markers, such as
vascular endothelial cadherin (VE cadherin), and acquire a mesenchymal or myofibroblastic
phenotype initiating expression of α-SMA, vimentin, and type I collagen. In addition, these cells
also become motile and are capable of migrating into surrounding tissues. Similar to EMT,
EndoMT can be induced by TGF-β (26,27).
Whereas investigations into the pathogenesis of fibrotic diseases have been ongoing for
many decades, discoveries within the last ten years have more fully characterized the molecular
complexity of the processes involved. Since its first identification in 1983 by Sporn and
collaborators (28-30) it has been known that transforming growth factor-ß (TGF-β) a pleiotropic
growth factor involved in the pathogenesis of numerous human diseases, plays a key role in
fibrotic diseases by stimulating the production of various collagens and other ECM components
5

by activated mesenchymal cells (29,31-33). TGF-β also inhibits the synthesis of matrix
degrading metalloproteinases and stimulates the production of tissue inhibitors of
metalloproteinases (34). However, multiple recent findings have clearly identified numerous
other cytokines including interleukins 4, 6, and 13 and several novel signaling pathways such as
the Wnt, Hedgehog and Notch as potential participants. Several other important new insights
have been made which have a critical bearing on therapeutic approaches for the fibrotic diseases.
There is a growing realization that the clinical manifestations and the molecular pathogenesis of
a given fibrotic disease are highly heterogeneous. As discussed above, besides the variety of
causes, often poorly understood, which may be responsible for initiating the fibrotic response
there is also increasing complexity at the cellular and molecular levels. Despite this
heterogeneity, however, the final common result is the excessive production of ECM. Thus, the
focus of this review will be on the cellular alterations and molecular pathways that play critical
roles in the fibrotic response and to discuss potential strategies that may allow identification of
potential therapeutic targets.
Critical Molecular Pathways Participating in the Fibrotic Response
Transforming Growth Factor Beta (TGF-β)
The TGF-βs comprise three structurally similar proteins, TGF-β1, TGF-β2 and TGF-β3,
with a wide and diverse spectrum of biological activities ranging from a role in embryonic
development to regulation of the immune response and to the development of exaggerated
fibrotic responses (35,36). Whereas deregulated TGF-β signaling occurs in essentially all fibrotic
reactions, the specific mechanisms vary depending on the causative agent(s) and on the affected
organ. TGF-β, initially produced as an inactive homodimeric peptide by numerous cell types,
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including fibroblasts and macrophages, is secreted into the ECM as a large latent complex
(Figure 2). The latent TGF-β complex consists of latent TGF-β binding protein covalently bound
to a small latency complex formed by a homodimer of TGF-β which is bound to an RGDcontaining N-terminal latency associated binding peptide (37,38). TGF-β can undergo several
alternative proteolytic or conformational activating events (39,40). Once activated TGF-β binds
to a constitutively active serine/threonine transmembrane receptor kinase known as TGF-β
receptor ll (TβRII). The intracellular transduction pathways following TGF-ß binding to its
cognate receptors are quite complex and involve either the Smad pathways or non-Smad
signaling pathways. The Smad pathways are often referred to as the canonical pathway whereas
the non-Smad pathways are referred to as the non-canonical pathways.
Canonical TGF-ß signaling pathways.
In the classic or canonical pathway the ligand-bound TβRII recruits and phosphorylates a TGF-β
receptor l (TβRI). The TβRl comprise a family of proteins also known as ALK proteins, two of
which, ALK-1 and ALK-5, are involved in TGF-β signaling (41-43). ALK-5 is the most
common TβRI and is phosphorylated by TβRII on three to five serine and threonine residues in a
short 30 amino acid regulatory sequence. Signaling from the TβRI to the nucleus then occurs
through the receptor activated RSmads, Smad2 or Smad3 which are phosphorylated by TβRl.
The phosphorylated Smad2/Smad3 then bind to the co-Smad, Smad4, forming a complex that
translocates across the nuclear membrane (44-48). In the nucleus the Smad complexes in
association with co-activators and co-repressors and other transcription factors modulate the
expression of target genes as illustrated in Figure 2. Fine tuning of TGF-β activity is achieved
through a balance of positive and negative effector molecules. Of critical importance is the
inhibitory Smad, Smad7, which inhibits TGF-β signaling through binding to TβRl receptor,
7

preventing recruitment and phosphorylation of RSmads and also facilitating TβRl degradation,
leading to inhibition of RSmad activation (49).
Non-Canonical TGF-ß signaling pathways. In addition to the Smad pathway, critical
profibrotic signaling cascades independent of RSmads can be activated in a cell-specific and
context-dependent manner and mediate important TGF-β effects (50,51). Of great importance
with respect to the fibrotic effects of TGF-β is the finding that TGF-β stimulation leads to the
activation of PI3K, which in turn activates two important profibrotic pathways: p21 activated
kinase (PAK2)-Abelson kinase (Abl) and Akt-mTOR1 pathways. Downstream targets of c-Abl
include known profibrotic mediators such as PKCδ/Fli-1, Egr, and Smad1 (52-55) as illustrated
in Figure 2. Activated c-Abl is required for the activation of Smad1 and for the phosphorylation
of protein kinase C-δ (PKC-δ), which in turn phosphorylates the transcription factor Fli-1
reversing its inhibitory effect on collagen gene expression. Furthermore, recent studies have
shown that the c-Abl-PKCδ pathway participates in the process of endothelial-mesenchymal
transition (26). The activation of Smad1 downstream of TGF-β is of particular interest since total
and phosphorylated Smad1 levels were significantly elevated in SSc skin biopsy samples and in
cultured SSc fibroblasts (54). The Akt-mTOR pathway plays an important role in various cell
processes including regulation of cell proliferation and metabolism as well as being involved in
some epithelial/mesenchymal transitions (56). Another important non-Smad signaling pathway is
through the activation of Jun N-terminal kinase (JNK) resulting in the activation of c-Jun, a
critical profibrotic transcription factor (50,51). In addition to serine/threonine phosphorylation,
TβRI can also be phosphorylated on tyrosine residues in response to TGF-β activation leading to
activation of Erk1/2 MAPK, which can play an important role by regulating myofibroblast
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formation as well as matrix synthesis (57-60). Other studies have shown that tyrosine
phosphorylation of TβRII, triggers activation of p38 MAPK signaling (61,62).
Connective tissue growth factor (CTGF/CCN2).
CTGF, also known as CCN2, is another pleotropic growth factor that has recently
emerged as an important mediator of normal and pathological tissue fibrotic responses (63,64)
and it has been suggested to play a crucial role in SSc tissue fibrosis (65,66). In vitro studies in
cultured fibroblasts have shown that the addition of recombinant CTGF or its overexpression
induced fibrosis. Furthermore, in experimental mouse models, elevated levels of CTGF were
associated with the development of fibrosis, and suppression of CTGF reduced bleomycininduced lung fibrosis (67). TGF-β stimulates CTGF synthesis in fibroblasts, vascular smooth
muscle cells and endothelial cells, and several studies have shown that CTGF acts as a
downstream mediator to enhance the fibrogenic action of TGF-β (68). Indeed, the CTGF
produced by these cells in response to TGF-β stimulation in turn stimulates the synthesis of such
ECM components as type I collagen and fibronectin in fibroblasts and very likely also in
endothelial cells (63,64). Significantly, Smad1 activation correlated with elevated CTGF protein
and CTGF promoter activity and DNA binding assays demonstrated that Smad1 was a direct
activator of the CTGF gene (54). Of considerable interest is the finding that imatinib mesylate,
an inhibitor of c-Abl, blocked activation of the Smad1 pathway in TGF-β stimulated normal
fibroblasts and abrogated stimulation of CTGF expression in SSc fibroblasts (54). These
observations indicate that, at least in some circumstances, c-Abl is required for Smad-1
activation. It should also be noted that CTGF expression can be independently stimulated
through the RhoA/ROCK pathway (69) as illustrated in Figure 2. Currently, trials testing antiCTGF antibodies in interstitial pulmonary fibrosis (IPF) and liver fibrosis are ongoing.
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Platelet derived growth factor
The platelet derived growth factor (PDGF) family consists of four different polypeptides,
the original PDGF-A and PDGF-B, and the more recently described PDGF-C and PDGF-D. The
biologically active PDGFs form disulphide-bonded dimers, such as PDGF-AA and PDGF-BB as
well as a PDGF-AB heterodimers. The PDGFs bind and activate two structurally related tyrosine
kinase receptors, PDGFRα and PDGFRβ. Ligand-induced receptor homo- or heterodimerization
leads to autophosphorylation of specific tyrosine residues within the cytoplasmic domain. PDGFA activates PDGFRα, exclusively, whereas PDGF-B is capable of activating PDGFRα,
PDGFRαβ and PDGFRβ. PDGF-AB can activate PDGFRα and PDGFRαβ (70-72). Receptor
activation leads to overlapping signal transduction pathways including PI3K, Ras-MAPK, Src
family kinases and phospholipase Cγ (PLCγ) resulting in various cellular responses including
proliferation, chemotaxis and actin reorganization as illustrated in Figure 3. Multiple reports
have implicated PDGF in fibrotic reactions of several organs, including pulmonary, renal and
hepatic fibrosis as well as in SSc (73). Fibroblasts are both major sources and targets for PDGFA since they express PDGFRα on their cell surface (74-76). Thus, PDGF-A/PDGFRα signaling
loops can stimulate fibroblasts to synthesize ECM and release pro-fibrotic mediators. PDGF-B is
primarily released by macrophages and hepatic stellate cells, with the latter ones also pointing to
a major role of PDGF-B/PDGFRβ-signaling in liver fibrosis (77,78). Upon tissue injury PDGF
signaling becomes activated to promote wound closure but PDGF signaling is tightly regulated
and turned off as soon as the physiologic repair processes are completed (79). Failure to
terminate activated PDGF signaling may lead to excessive scar formation and tissue fibrosis.
Wnt-Signaling
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While β-catenin has a structural role linking transmembrane cadherins to the actin
cytoskleton, it also plays a critical role in canonical Wnt signaling. In the absence of Wnt
signals, β-catenin binds to and is phosphorylated by a complex consisting of adenomatosis
polyposis coli (APC), axin, glycogen synthase kinase-3β (GSK-3β), and casein kinase which
promotes subsequent degradation of β-catenin. Wnt proteins are secreted ligands that transmit
their signal across the plasma membrane by interacting with Frizzled receptors and low-density
lipoprotein receptor-related protein co-receptors (LRP5/6) as illustrated in Figure 3 (80). Wnt
receptor binding disrupts the complex resulting in the stabilization of β-catenin which
translocates to the nucleus, where it binds to T-cell factor/lymphoid enhancer-binding factor
(Tcf/Lef) to induce target gene transcription such as axin-2 (81). Aberrant activation of the
canonical Wnt signaling pathway has been implicated in a variety of pathological processes
including pulmonary, renal, dermal and liver fibrosis, as well as, in scarring following
myocardial infarction and fibrosis accompanying muscular dystrophy (82-86). Wnt signalling is
tightly controlled by an array of negative regulators, among which, Dickkopf proteins (Dkk-1–4)
have a key role. The best studied is Dkk-1, which functions as a natural secreted antagonist of
Wnt signaling (87,88).

Hedgehog Signaling
Mammalian orthologs of the Drosophila melanogaster hedgehog (Hh) morphogen are
highly hydrophobic secreted peptides and three different hedgehog proteins have been described,
Sonic hedgehog (Shh), Indian hedgehog, and Desert hedgehog with Shh being the most
important in the present context (89). Patched (Ptc), a twelve-pass membrane protein binds Hh
ligands, but in the absence of ligand, Ptc interacts with and inhibits Smoothened (Smo), a sevenpass membrane protein (90). However, binding of Shh to Ptc1 induces conformational changes
11

that prevent Ptc1 from inhibiting Smo. The absence of Smo inhibition initiates a series of
intracellular events resulting in stabilization of Gli family zinc finger transcription factors which
in turn stimulate expression of Hh target genes (91) as illustrated in Figure 3. While Hh signaling
is critical during embryonic development, inappropriate activation has been implicated in the
pathogenesis of various diseases in adults, including a variety of malignancies (92-94). A recent
study has shown that overexpression of Shh in cultured SSc fibroblasts activates the Hh pathway,
with accumulation of the transcription factor Gli-2 and increased expression of Hh target genes
(95). Furthermore, Shh potently stimulated the production of collagen and induced the
differentiation of resting fibroblasts into myofibroblasts. Overexpression of Shh in the skin of
mice was sufficient to induce fibrosis, and mice lacking one allele of the gene for the inhibitory
receptor Ptc1 were more sensitive to experimentally-induced fibrosis (95).

Notch Signaling
Notch signaling, also first discovered in Drosophila, is initiated by binding of members
for two ligand families, Jagged and Delta-like. Binding of ligands such as Jagged-1 (Jag-1)
results in cleavage of Notch receptors by the γ-secretase complex and release of the active Notch
intracellular domain (NICD) as illustrated in Figure 3 (96,97). Translocation of the NCID into
the nucleus activates the transcription of numerous target genes such as the Hairy/Enhancer of
Split (Hes) (98). Abnormal Notch signaling participates in the pathogenesis of several human
diseases including T-cell acute lymphoblastic leukemia and melanoma (99,100). Clinical trials
with γ-secretase inhibitors already in progress in patients with T-cell acute lymphoblastic
leukemia have yielded promising results (101). There is accumulating evidence for the
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importance of Notch signaling in fibrotic diseases, although the molecular mechanisms involved
in fibroblast activation and stimulation of ECM synthesis need clarification (102,103).
Endothelin-1

Endothelin-1 (ET-1) is a 21-amino acid polypeptide with potent vasoconstrictor activity
that plays a crucial role in the pathophysiology of pulmonary arterial hypertension and has been
identified as a prime therapeutic target for this disorder (104,105). A growing body of evidence
has implicated ET-1 as a participant in organ fibrosis and numerous studies have described a
variety of its profibrogenic activities. ET-1 has been shown to stimulate the synthesis of
extracellular matrix macromolecules such as collagen types I and III and to inhibit the production
of matrix degrading metalloproteinase-1 in cultured normal human fibroblasts (106,107).
Furthermore, increased production of ET-1 has been demonstrated in a variety of human fibrotic
diseases (108) and in experimentally induced pulmonary fibrosis (109) providing strong support
to the concept that ET-1 also plays an important role in the pathophysiology of SSc, pulmonary
fibrosis and other fibrotic diseases (110-112). ET-1 also was found to be involved in the
induction of EMT (113). The role of ET-1 in EMT appears to be mediated through the
endothelin A receptor (ET-A) via stimulation of endogenous TGF-β1 production (114).

Strategies for Inhibition of Fibrosis
Cellular phenotypic transitions resulting in myofibroblast formation. Recent delineation of
the cellular phenotype transitions leading to the activated myofibroblast and the molecular
identification of the pathways stimulating the fibrogenic processes have suggested new
therapeutic approaches and targets. As discussed above and shown in Figure 1, there are four
distinct potential cell sources of myofibroblasts. Three of these may be found as residents in the
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affected tissue including fibroblasts, endothelial cells and epithelial cells. Thus blocking their
transition into activated myofibroblasts could prevent the initiation of the fibrotic process itself.
The most direct transition is the conversion of fibroblasts into myofibroblasts in which the
activated cells express α-SMA and synthesize markedly increased amounts of ECM components.
Undoubtedly, TGF-β is the most important causative agent involved in the fibroblast activation
process as well as the mesenchymal transformation of epithelial and endothelial cells. Thus,
preventing TGF-β action is clearly a potential therapeutic approach that may be achieved at
several levels.
Interfering with TGF-β expression and activation. The complex signaling pathways
initiated by TGF-β receptor binding offer multiple points of potential therapeutic intervention.
TGF-β is constitutively synthesized and stored in an inactive form as a complex with specific
binding proteins. Thus, the expression of TGF-β and the process of its release in an active form
present therapeutic targets. Pirfenidone has been studied in experimental models of pulmonary
fibrosis in which it suppressed TGF-β gene expression at the transcriptional level and
significantly reduced the tissue levels of TGF-β mRNA and TGF-β in lavage fluid (115).
Pirfenidone has been evaluated in four randomized, double-blind, placebo-controlled clinical
trials. The collective results of these trials indicate that pirfenidone can reduce the rate of decline
in lung function as measured by changes in forced vital capacity or total lung capacity but had
little effect on diffusing capacity or resting arterial oxygen levels (116,117)
Several αv integrins can activate matrix-bound latent TGF-β and antibodies to the
integrin αvβ6 expressed on epithelial cells blocked the activation of TGF-β preventing
development of experimental lung fibrosis (118-120). Such a specific antibody approach has the
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advantage of confining the blocking activity only to injury sites where αvβ6 is expressed only in
epithelia and not compromise other important functions of TGF-β.
Angiotensin ll in certain circumstances exhibits remarkable profibrotic properties
probably acting, at least in part, through stimulation of TGF-β production (121,122). Although
angiotensin converting enzyme and AT1R inhibitors can block experimental models of lung
fibrosis, there are no published reports regarding the use of these drugs in humans with
pulmonary fibrosis. Therefore, it is still unclear whether ATll inhibition would have beneficial
effects in fibrotic conditions, although the complex interactions between TGF-β and ATll
suggest that pharmacologic inhibition of both systems may yield synergistic beneficial effects.
Blocking or inactivating extracellular TGF-β is a possible approach but results to date in
humans have so far not been promising even though a TGFβ1 inhibitor peptide attenuated the
progression of lung fibrosis in the bleomycin pulmonary fibrosis model (123). In a phase l/ll
double-blind, placebo controlled trial of CAT-192, a human anti-TGFβ1 monoclonal antibody in
patients with early diffuse SSc no improvement was found in the extent or severity of skin
involvement or in lung function parameters (124). Also because of the wide-ranging functions of
TGF-β, interfering globally with this essential signaling molecule could have untoward, toxic
effects as was the case in the CAT-192 clinical trial (124).
Inhibition of homing of circulating profibrotic cells. Circulating fibrocytes which
express the CXCR4 receptor migrate to fibrotic sites in response to CXCL12 chemokine
gradients and the CXCL12/CXCR4 axis appears to be up-regulated in SSc (125). CXCL12
antagonizing antibodies as well as AMD3100, a CXCR4 antagonist significantly reduced
bleomycin-induced lung fibrosis (126,127). AMD3100 is approved for the treatment of some
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malignancies such as non-Hodgkin’s lymphoma, thus targeting the CXCL12/CXCR4 axis with
available drugs represents a potentially effective anti-fibrotic therapeutic strategy.
Various experimental studies as well as ex vivo human data support a pro-inflammatory
and pro-fibrotic role for the monocyte chemoattractant protein-1 (MCP-1/CCl-2). Inhibition of
MCP-1 signaling by blocking its receptor, CCR2, reduced the accumulation of ECM proteins in
animal models of skin and lung fibrosis (128). Since antagonists of CCR2 are currently in
clinical trials for various diseases, they may also be evaluated as anti-fibrotic agents.

Blocking TGF-β signaling pathways (see Figure 2).
Inhibition of TGF-β receptor and canonical signaling.

There

have

been

several

studies of specific inhibitors of TGF-β type l receptor and the most thoroughly studied is SM305
which proved to have excellent selectivity and potency against ALK5 and ALK4. In normal
dermal fibroblasts, SM305 abrogated TGF-β-induced ECM gene expression, fibrogenic cytokine
production,

Smad3-

and

Smad2-dependent

transcriptional

responses,

and

fibroblast

transdifferentiation into myofibroblasts (129). These inhibitory effects of SM305 were associated
with potent selective suppression of TGF-β-induced phosphorylation and nuclear translocation of
R-Smads. However, in unstimulated SSc fibroblasts, SM305 only caused variable and modest
reduction in levels of type I collagen, and did not reverse constitutive Smad nuclear
accumulation or the proportion of α-SMA-positive myofibroblasts. Together, these results
indicate that ALK5-Smad signal transduction plays a fundamental role in mediating TGF-βdependent profibrotic responses in normal fibroblasts, whereas Smad nuclear accumulation in
SSc fibroblasts appears to be ALK5 independent. In light of its potent antifibrotic activities in
normal dermal fibroblasts in vitro and in vivo, SM305-mediated ALK5 inhibition represents a
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novel therapeutic strategy for controlling some TGF-β driven fibrotic conditions. The apparently
contradictory results in SSc fibroblasts emphasize the complexity and heterogeneity of fibrotic
reactions and the requirement to appropriately select therapeutic approaches to specific diseases.

Specific inhibition of Smad3. SIS3 is a potent and selective inhibitor of Smad3 that has
been shown to block the phosphorylation of Smad3 induced by TGF-β without affecting the
phosphorylation of Smad2 (130). SIS3 also inhibited the interaction of Smad3 with Smad4 as
well as the stimulation of collagen production by TGF-β by normal fibroblasts and their
transition to myofibroblasts. Significantly, SIS3 completely blocked the constitutive
phosphorylation of Smad3 as well as the increased type I collagen expression in SSc fibroblasts.
The effects of SIS3 on EndoMT and on experimentally-induced diabetic nephropathy were
studied recently (131). EndoMT was induced in a mouse microvascular endothelial cell line
(MMEC) through the use of advanced glycation end products (AGEs) and diabetic nephropathy
was induced in mice by administration of streptozotocin (STZ) (124). SIS3 abrogated EndoMT
in the MMEC, and reduced renal fibrosis and retarded progression of nephropathy in the STZtreated mice. Together, these studies suggest that SIS3 may prove to be an effective anti-fibrotic
agent in selected diseases.

Selective inhibition of TGF-β non-canonical signaling pathways. A variety of targets
present themselves when viewing the multiplicity of components encompassing the noncanonical pathways initiated by TGF-β. Most prominent among these is the non-receptor
tyrosine kinase, cAbl. The role of c-Abl in the fibrogenic process was serendipitously discovered
when patients receiving treatment with imatinib mesylate (Gleevec) for chronic myelogenous
leukemia (CML) caused by Bcr-Abl translocation had a remarkable reduction of bone marrow
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fibrosis (132). Imatinib mesylate is a small molecule that specifically inhibits several tyrosine
kinases including c-Abl, PDGFR, c-kit and c-fms by blocking the binding of ATP to the active
kinase site. Imatinib mesylate has been shown to be effective in preventing the development of
organ fibrosis in the kidney, lung, liver, and skin in several animal models (133-138). As seen in
Figure 2 and 3, inactivating c-Abl blocks several downstream effector molecules required for the
full TGF-β response, while simultaneous inhibition of PDGF potentiates its anti-fibrotic effect.
Imatinib has been used extensively and successfully in the treatment of CML and
gastrointestinal stromal tumors with relatively little toxicity. However, the results in clinical
trials of fibrotic diseases have been less clearcut. To date in five small clinical trials and several
case reports a total of 108 patients with severe SSc have been treated with imatinib. Encouraging
results were reported in 3 of 4 of these studies whereas the fifth study was prematurely
terminated for safety reasons (139). In contrast, a recent trial of imatinib in patients with IPF
failed to accomplish the primary outcome measures with little beneficial effect on survival or
lung function improvement, possibly owing to the short term treatment period of only six months
(140). However, in phase ll and lll clinical trials imatinib had a potent and prolonged beneficial
effect on pulmonary arterial hypertension and reversed vascular remodeling even when already
established (141).
Second generation and wide spectrum tyrosine kinase inhibitors. A significant
fraction of the patients treated in the imatinib anti-fibrotic trials withdrew because of mild to
moderate side effects. Dasatinib and nilotinib are second-generation tyrosine kinase inhibitors
with improved toxicity profiles that have proven effective in animal models of SSc and both of
them require only nanomolar concentrations to obtain strong target inhibition compared to the
micromolar concentrations required with imatinib (142). In addition to c-Abl and PDGFR,
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dasatinib inhibits sarcoma-tyrosine (src) kinases which regulate c-Abl and are activated by TGFβ and PDGF. A specific inhibitor of src kinases, SU6656, reduced skin fibrosis in experimental
models of SSc (143). However, no clinical data is currently available for either of these drugs.
Nintedanib (BIBF 1120) is a potent intracellular inhibitor of tyrosine kinases that is in
clinical development for the treatment of IPF and various cancers (144). Its targets include
(PDGFR), vascular endothelial growth factor receptors (VEGFR), and fibroblast growth factor
receptors (FGFR). Because signaling pathways activated by these tyrosine kinase receptors have
been shown to be involved in lung fibrosis (145) and other fibrotic processes their inhibition may
slow progression of IPF or liver fibrosis (146-149). In a rat model, such inhibition was shown to
prevent the development of bleomycin-induced lung fibrosis when nintedanib was administered
before or during the fibrotic phase of the disease (147). In a recently published clinical trial for
IPF (150), nintedanib at the highest dose employed produced a significant improvement in the
decline of forced vital capacity compared with the placebo group. This dose also resulted in a
lower incidence of acute exacerbations as compared with placebo with relatively mild and
tolerable side effects. Given the intractable nature of IPF, these results suggest that wide
spectrum tyrosine kinases may prove useful in treatment of fibrotic diseases.

Rho-asssociated kinases
The intracellular mechanisms by which cytokines and growth factors such as TGF-β
activate fibroblasts and stimulate ECM production are not completely understood. The small
GTPase RhoA plays a central role in cell motility and adhesion through reorganization of the
actin cytoskeleton. Activation of receptors switches RhoA from an inactive, GDP-bound
conformation to an active GTP-bound conformation, which binds to and activates target
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molecules (151). Cellular responses to RhoA are mediated by downstream Rho-associated
kinases (ROCK) (152,153), which reorganize the actin cytoskeleton through phosphorylation of
several substrates that contribute to the assembly of actin filaments and contractility, molecular
events critical for the differentiation of resting fibroblasts into active myofibroblasts. When
cultured fibroblasts were treated with TGF-β, inhibition of ROCK with the specific inhibitor
Y27632 blocked the formation of myofibroblasts and reduced ECM production without cell
toxicity (154). The MAP kinase ERK, identified as a down-stream target of ROCK in SSc
fibroblasts, played a critical role in the profibrotic response to TGF-β treatment. It is not certain
how ERK mediates its fibrotic effects, but it may regulate Smad3 signaling in certain cells or it
may activate the transcription factor Sp1 which can stimulate transcription of the type I collagen
genes and which is elevated in fibrotic conditions including SSc (155-158). Interestingly, two
DNA intercalators, WP631 and mitoxantrone, have been shown to prevent binding of Sp1 to the
COL1A1 promoter in human dermal fibroblasts. Both drugs inhibited basal COL1A1 production
and mRNA levels without cytotoxicity or apoptosis and prevented TGF-β stimulation of
expression (159). These data suggest that Sp1-DNA intercalators may be an effective approach
for the treatment of fibrotic diseases.
Inhibitors of hydroxymethylglutaryl-coenzyme A reductase such as statins, which are
widely used to lower serum cholesterol, have been shown to have anti-fibrotic effects (160-162),
which might be mediated by inhibition of ROCK. Statins interfere with the geranylgeranylation
of membrane RhoA (163,164), which prevents the activation of RhoA, which in turn blocks the
activation of Rock. Furthermore, a specific inhibitor of geranylgeranyl transferase 1 inhibited
type I collagen gene expression in normal and SSc fibroblasts (165). Thus, the antifibrotic
activity of statins supports the antifibrotic effects of ROCK inhibitors. The ROCK inhibitor,
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fasudil, has been used in Japan and China for the treatment of coronary and cerebral artery
vasospasm (166,167). Considering the very low rate of side effects and the favorable clinical
experience in those studies, ROCK inhibitors should be considered as promising candidates for
targeted anti-fibrotic therapy.

Caveolin-1
Caveolin-1, the most important structural component of caveolae, is also found in several
other cellular sites and is expressed in a variety of cell types including epithelial cells,
endothelial cells and fibroblasts. Of interest in the present context is its potential role in
regulation of the fibrotic reaction and prominent in this regard is its ability to bind and inhibit a
substantial number of kinases (168). High levels of caveolin-1 are found in normal lung
fibroblasts, whereas much lower levels are found in lung fibroblasts from fibrotic lungs of SSc
and IPF patients (169-171). This reduction in caveolin-1 is associated with increased activity of
several signaling kinases (MEK, ERK, JNK, Akt) and increased expression of matrix molecules.
An interesting finding is the localization in caveolin-1 of the binding site which functions as a
kinase inhibitor (amino acids 82-101) known as caveolin-1 scaffolding domain (CSD). When
fused to the C terminus of the Antennapedia internalization sequence, CSD can enter cells with
low caveolin- concentrations where, like the intact molecule, it can bind kinases, inhibit their
activity and also inhibit collagen expression (171). In caveolin-1 null mice, alveolar walls are
thickened, the diameter of alveolar spaces is reduced, and ECM is significantly increased (172174). In the bleomycin lung fibrosis model caveolin-1 levels are depressed, and systemic
administration of CSD blocks the fibrotic process (170), suggesting a causal relationship
between low caveolin-1 levels and lung fibrosis.

21

TGF-β and caveolin-1 signaling interact in several ways. TGF-β inhibits caveolin-1
expression in several types of cells including lung and dermal fibroblasts, while caveolin-1
modifies TGF-β signaling by inhibiting Smad3 phosphorylation and its translocation to the
nucleus (175). Caveolin-1 also regulates TGF-β signaling through its effects on the endocytosis
of TGF-β ligand-receptor complexes, which are present in both caveolin-1 rich lipid rafts and
clathrin-rich early endosomes (176,177).

Early endosomal internalization increases TGF-β

signaling while caveolin-1-rich lipid raft internalization leads to receptor degradation and
inhibition of TGF-β signaling (176). Thus, the loss of caveolin-1 in fibrotic tissues will promote
TGF-β signaling by early endosomal internalization.
The above discussion must be viewed with some caution, however, since other reports
have found higher levels of caveolin-1 in some SSc dermal fibroblasts than in normal dermal
fibroblasts and found that caveolin-1 overproduction enhanced collagen expression while
caveolin-1 depletion inhibited collagen expression (178,179). Furthermore, caveolin-1 was found
to be a positive regulator of phospho-Smad1 and CTGF, a powerful profibrotic cyokine (178).
In spite of these caveats, the use of CSD as a molecular therapeutic must be considered
for treating certain fibrotic conditions, such as in the lung, because caveolin-1 regulates several
signaling pathways which may be a more effective approach than use of agents targeting a single
specific pathway.

Transcription and other intracellular factor modulation
The c-Abl/PKCδ/Fli-1 pathway. As discussed above, c-Abl has a critical role in
mediating the fibrotic response intiated by TGF-β. An important part of this activity is the
phosphorylation/activation and nuclear localization of PKCδ. PKCδ then phosphorylates the
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transcriptional repressor Fli1 at threonine 312 which promotes its interaction with p300/CREBbinding protein-associated factor and subsequent acetylation. These molecular events cause Fli-1
dissociation from the human α2(I) collagen gene promoter, resulting in enhanced transcription of
the gene (see Figure 2) (180). A breakthrough study on the role of PKCδ in the regulation of
collagen gene expression found that selective inhibition of PKCδ markedly decreased the
production of collagen by SSc fibroblasts (181,182) and a very specific peptide inhibitor of
PKCδ is now being investigated as a protective agent for reperfusion injury after myocardial
infarction (183). Previous extensive animal experiments have shown this peptide to be a highly
effective and specific inhibitor of PKCδ with minimal toxic effects, suggesting its potential
utility in fibrotic disorders.
The AP-1 transcription factor family. The transcription factor AP-1 is a heterodimeric
molecule composed of members of the Jun (c-jun, junB and junD) and the Fos family (cFos,
FosB, Fra-1 and Fra-2). Currently, the most important of these with respect to fibrotic conditions
are c-Jun, JunD, cFos, and Fra-2. TGF-β stimulated the expression of Fra-2 in dermal fibroblasts
through ERK signaling and JunD through Smad3 pathway (184). JunD, cJun and cFos were
found to be overexpressed in the skin and dermal fibroblasts of SSc patients (185). Interestingly,
the effects of AP-1 on collagen synthesis seem not to be restricted to SSc dermal fibroblasts but
might also occur in cardiac, renal, and keloid fibroblasts (186-188). These are important findings
since they suggest that a critical mode of TGF-β profibrotic activity is through up-regulation of
AP-1 and its resultant transcriptional activity. In this regard it should be noted that AP-1 upregulates

tissue

inhibitor

of

metalloproteinases

(TIMP)

while

decreasing

matrix

metalloproteinase-1 (MMP-1) (189). Thus, AP-1 not only increases the production of matrix
components, but also inhibits their degradation resulting in their net accumulation.
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T-5224 is a small molecule inhibitor of AP-1 that was developed based on the x-ray
crystal structure of the basic region leucine zipper domain of the AP-1–specific DNA complex
composed of c-Jun/c-Fos. In a preclinical animal study, T-5224 had an excellent safety profile
(190). T-5224 blocked the in vitro effects of TGF-β on the differentiation of resting fibroblasts
into myofibroblasts and stimulation of ECM production and in vivo prevented dermal fibrosis
induced by bleomycin (185). Because of the potent antifibrotic effects and the favorable safety
profile of T-5224, inhibition of AP-1 signaling by T-5224 and other similar potential agents must
assume a high priority for the treatment of fibrotic diseases in well-controlled clinical test
settings.
In contrast to the pathways used in the up-regulation of expression of c-Jun by TGF-β
and PDGF, activation of c-Jun by phosphorylation proceeds through the activity of c-Jun Nterminal kinase (JNK). The selective JNK inhibitor, CC-930, prevented the phosphorylation of
cJun, reduced the stimulatory effects of TGF-β and PDGF on collagen production, prevented
collagen accumulation and dermal thickening in bleomycin and Tsk-1 mice experimental fibrotic
models, and, highly remarkably, it induced regression of established experimental fibrosis (191).
Phase III clinical trials with various inhibitors of JNK for the treatment of rheumatoid arthritis
and different types of cancer showed that inhibition of JNK is well tolerated in humans (192).
Mice treated with CC-930 did not show any signs of toxicity and initial results from dosing
studies in healthy human volunteers have indicated that CC-930 is well tolerated (193). Thus,
JNK is a viable target for treatment of fibrotic diseases.

JAK2 and Stat3. Janus kinases (JAKs) are receptor-associated tyrosine kinases with
central roles in cytokine- and growth factor signaling. Upon cytokine binding to the receptor,
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JAK kinases become activated and phosphorylate tyrosine residues in the cytoplasmic region of
the receptor (194). STATs (Signal Transducer and Activator of Transcription) are latent
cytoplasmic transcription factors that are recruited to these phosphorylated receptor sites and
become activated by phosphorylation by JAKs of a conserved tyrosine residue near the Cterminus after recruitment to an activated receptor complex. Activated STATs then dimerize and
translocate into the nucleus where they activate transcription of several target genes (194). JAK2
is a key-regulator of cytokine signaling and alterations of JAK2 signaling cause profound
changes in response to cytokine stimulation. Point mutations in the JAK2 gene, which result in
constitutive activation of JAK2, are critical in the pathogenesis of myeloproliferative diseases
(194,195) and this critical role has stimulated the development of JAK2 inhibitors, several of
which are currently being evaluated in clinical trials with promising results (196).
Increased activation of JAK2 and STAT3 were detected in the skin of SSc patients,
which persisted in cultured SSc fibroblasts (197). The selective JAK2 inhibitor, TG 101209,
reduced basal collagen synthesis in SSc fibroblasts and prevented the stimulatory effects of
TGFβ on fibroblasts. Treatment with TG 101209 not only prevented bleomycin-induced fibrosis,
but also effectively reduced skin fibrosis in the Tsk-1 mice animal model of tissue fibrosis (197).
JAK2 may not only act as a downstream mediator of TGF-β but may also amplify TGF-β
signaling by stimulating the expression of TGF-β since incubation with TG 101209 caused a
dose-dependent decrease in the mRNA levels of TGF-β in SSc fibroblasts. Furthermore, other
studies demonstrated that inhibition of STAT3 and overexpression of suppressor of cytokine
signaling 1 (SOCS1) reduced the expression of TGF-β (198,199). Considering that several
pharmacological inhibitors of JAK2 are available and appear to be well tolerated, targeting JAK2
for the treatment of fibrotic diseases deserves careful consideration.
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Peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ is a nuclear
receptor originally identified in adipose tissue but is broadly expressed and plays a crucial role in
glucose and lipid metabolism. Recent studies have described new functions for PPARγ in the
regulation of connective tissue homeostasis. A decrease in PPARγ expression accompanied
progression of fibrosis in experimental models of lung, liver and kidney fibrosis and was a
consistent finding in skin and lung tissues from SSc patients (200). In addition, adiponectin
levels, a sensitive and specific index of PPARγ activity, were reduced in the serum of patients
with diffuse cutaneous SSc and correlated inversely with the extent and severity of skin sclerosis
(201). Thus, adiponectin might have potential as a biomarker in SSc. Several profibrotic factors
such as TGF-β, Wnt proteins and IL-13 suppress PPARγ activity or expression (202). Treatment
of normal fibroblasts with the endogenous PPARγ prostanoid ligand, 15d-prostaglandin J2, or
with the PPARγ pharmacologic agonist, rosiglitazone, abrogated TGF-β induced fibrotic
responses (203-205). In addition, PPARγ blocks EMT and the differentiation of preadipocytes
into fibroblasts (206), a putative novel mechanism of tissue fibrosis. Since rosiglitazone is
already used in the treatment of diabetes mellitus, evaluation of it as an anti-fibrotic agent in
clinical trials appears warranted.

Inhibition of other profibrotic signaling pathways
Wnt signaling. TGF-β appears to be the major factor activating the canonical Wnt pathway in
fibrotic diseases probably mediated largely by a decrease of Dkk-1 and although other molecular
mechanisms are possible, the addition of recombinant Dkk-1 blocked the stimulatory effects of
TGF-β on the canonical Wnt pathway in fibroblasts (207). Wnt signaling caused the transition of
resting fibroblasts into activated myofibroblasts, and increased the production of ECM
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components. Dkk-1 is currently being investigated as a potential therapeutic target in other
diseases and the cumulative data suggest that inhibition of the canonical Wnt pathway might be
an effective approach to target TGF-β signaling in fibrotic diseases
Hedgehog signaling. Abnormal stimulation of Hh signaling might be driven by several factors.
Hypoxia at levels similar to those observed in skin of SSc patients induces the expression of Shh
(208,209). However, a more likely general scenario is that profibrotic cytokines including TGFβ, PDGF, and Wnt drive Shh overexpression (210-212). It has been shown that Shh stimulated
resting fibroblasts to differentiate into myofibroblasts and that overexpression of Shh in mice
caused accumulation of collagen and dermal thickening (213). Thus, Hh signaling might play a
central role in the pathogenesis of fibrosis. Both Smo-specific siRNA or the small-molecule
inhibitor LDE223, a highly selective antagonist of the Hh coreceptor Smo effectively blocked the
aberrant activation of the hedgehog pathway while LDE223 prevented bleomycin-induced
dermal fibrosis (214). In addition, treatment of Tsk-1 mice with LDE223 prevented progression
of fibrosis and induced its regression (214). Several small molecule inhibitors of Smo including
LDE223 are currently being evaluated in clinical anti-cancer trials with minimal side effects
reported so far. Thus, pharmacologic inhibition of the Hh pathway might be a promising
approach to treatment of fibrotic disorders as illustrated in Figure 3.

Notch signaling. Recent studies in SSc skin suggest that infiltrating T cells expressing the Jag-1
ligand might activate Notch signaling in fibroblasts leading to their transition to myofibroblasts
with increased expression of ECM (102,103). Although Notch signaling may be induced under
hypoxic conditions or by TGF-β, the detailed molecular mechanisms responsible for this
transition remain to be determined (215-217). Such activation of Notch signaling has also been
found in mouse models of dermal fibrosis (218). Treatment with the γ-secretase inhibitor DAPT,
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which blocks Notch signaling, significantly decreased experimental pulmonary and dermal
fibrosis in mice and in SSc dermal fibroblasts (102,219). Since various inhibitors of γ-secretase
are in clinical trials for different types of malignancies, similar trials in fibrotic diseases appear
both feasible and warranted.

Other important pathogenetic mechanisms in fibrotic diseases

Role of micro RNAs in Fibrosis. MicroRNAs (miRNAs) are small (~22 nucleotides),
evolutionarily conserved non-coding RNA which modulate the expression of protein coding
genes at the post-transcriptional level by binding complementarily to the 3’ untranslated region
(UTR) of target mRNAs and suppress expression by either inhibiting mRNA translation or
facilitating mRNA degradation (220). Approximately 1400 miRNAs have been identified to date
in humans with most miRNA genes being located in introns, exons and UTRs of protein coding
genes (221). Although the role of miRNA in cancer has been extensively studied, recent interest
has been devoted to elucidating their participation in tissue fibrosis and fibrotic diseases (222).
Several miRNA, including let-7, miR-21, mir-29 and miR-155 are regulated by TGF-β and their
targets are mRNAs coded by genes involved in matrix homeostasis such as those encoding
collagens, matrix metalloproteinases, and Smad signaling proteins. miR-29 and let-7 are
antifibrotic (223) whereas miR-21 and miR-155 are profibrotic and their expression is increased
in fibrotic reactions (224). Conversely, miR-29 was found to be markedly down-regulated in SSc
dermal fibroblasts and skin (225). Overexpression of miR-29 in SSc fibroblasts decreased the
levels of type 1 and type lll collagens demonstrating a direct effect of miR-29. Similar reduction
of miR-29 was observed in fibrotic reactions in other organs, including heart, kidney and lung.
TGF-β, PDGF-B or IL-4 reduced the levels of miR-29 in normal fibroblasts to levels similar to
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those observed in SSc fibroblasts and a marked reduction was also seen in the bleomycin model
of skin fibrosis (225). Although hypothetically regulation of miRNA expression could be
therapeutically exploited, presently there are considerable practical barriers to

its

implementation.

The Immune Response and Fibrotic Reactions. In many instances, a persistent inflammatory
reaction characterized by accumulation of immune cells including various lymphocyte
populations and macrophages and the release of growth factors and cytokines by these cells lead
to activation of myofibroblasts and a fibrotic response. Owing to space limitations and to the
availability of several outstanding recent reviews covering the immunologic and inflammatory
aspects of tissue fibrosis (226,227), the present discussion will be confined to a brief review of
the direct involvement of the immune response in promoting or inhibiting fibrogenesis. Of
singular importance in this regard is the role of Toll-like receptors (TLRs) which are activated
not only by microbial ligands termed pathogen-associated molecular patterns (PAMPs) which
are specifically recognized by TLRs, but also a variety of ligands derived from host components
collectively referred to as damage-associated molecular patterns (DAMPs) as well as nucleic
acid-containing immune complexes (228). TLRs are found not only in cells of the immune
system but also in fibroblasts. Type I interferon production, linked to innate immune signaling
through TLRs, can result in TLR3-mediated responses in normal skin fibroblasts (229). While
TLR3 is an endosomal receptor, TLR4 is expressed on the fibroblast cell surface and can
recognize various DAMPs. Although activation of TLR4 induces a modest fibrotic reaction by
itself, it stimulates a synergistic response in association with TGF-β (230). Thus, fibroblast
innate immune signaling might be a critical contributor to the perpetuation of a profibrotic
response.
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The adaptive immune response is complex in that it contributes both profibrotic and
antifibrotic aspects. The TH2 profibrotic responses, are characterized most importantly by the
production of IL-13, which has been shown to be a potent stimulator of fibroblast proliferation
and collagen production and when overexpressed induced skin and lung fibrosis in various
experimental models (231). Elevated levels of IL-13 have been found in patients with SSc and it
has been implicated in the pathogenesis of IPF, experimental lung fibrosis, SSc, and liver fibrosis
(232-234). A recent study demonstrated that IL-13 signaling via IL-13Ra(2) activated AP1
which then stimulated the transcriptional activity of the TGF-β promoter. In contrast, the
inhibition of IL-13 signaling reduced the production of TGF-β and markedly reduced collagen
deposition in bleomycin-induced pulmonary fibrosis (235). There are two phase II, double-blind
placebo, randomised-controlled trials currently ongoing in SSc-ILD and IPF in which a fully
humanized monoclonal antibody against human IL-13 is being tested.

TH1 effector T cells, as well as natural killer and natural killer T cells, produce IFN-γ
which inhibits fibrosis, at least in part, by antagonizing the activity of TGF-β. IFN-γ inhibits the
phosphorylation of Smad3 as well as inducing the expression of inhibitory Smad7 (236-238).
IFN-γ also blocks the TH2 cytokine-induced differentiation of peripheral blood monocytes into
fibrocytes (239). In spite of this supporting evidence, clinical studies testing the therapeutic
potential of IFN-γ in IPF, SSc and other fibrotic disorders have been mostly disappointing (240).

IL-17A, expressed by TH17 cells, has been implicated in the pathogenesis of pulmonary,
cardiac and hepatic fibrosis (241-243). The proinflammatory cytokines IL-1β and IL-23 have
been identified as initiators of TH17 responses and it has been found that in some circumstances
TGF-β may partially exert its fibrotic effects through IL-17A production (241,244). Extracellular
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bacteria and certain fungi can lead to inflammasome activation and IL-6 production, which in the
presence of TGF-β1, can drive TH17 differentiation (226). Il-6 has been reported to be upregulated in the serum, dermal fibroblasts and peripheral blood mononuclear cells of SSc
patients, and found to correlate with the extent of skin fibrosis (245). Blocking of IL-6 in vitro
decreased collagen production, and IL-6 deficiency attenuated lung fibrosis in the bleomycin
model (246). Tocilizumab, a humanized monoclonal antibody directed against the IL-6 receptor,
has been approved for the treatment of RA. Although preliminary data in a small number of
patients from one study on the effects of tocilizumab on polyarthritis in SSc patients did not
show any change in the extent of cutaneous involvement over a 6-month period (247), there is a
currently ongoing trial to examine the effects of tocilizumab in diffuse SSc.

Role of Reactive Oxygen Species (ROS) in Fibrotic Diseases
Numerous studies have provided compelling evidence for the involvement of ROS in the
development of tissue fibrosis (248-250). Although ROS are produced under physiological
conditions and are essential for many intracellular reactions including fibroblast proliferation,
there is evidence that SSc fibroblasts produce ROS constitutively and that elevated ROS levels
may be involved in the increased collagen expression in these cells (251). In addition increased
urinary 8-oxodG levels in SSc patients suggest marked oxidative stress (252). Although several
classes of enzymes can produce ROS, in the present context the most important is the NADPH
oxidase (NOX) family of oxidoreductases, especially NOX4 which is the most widely distributed
isoform. NOX4 is one of seven NADPH isoforms and like the others its structure consists mainly
of a six-transmembrane domain known as the gp91phox domain (253,254). Despite their
extensive similarity in structure and enzymatic function, members of the NOX family differ in
their mechanism of activation. In particular, NOX4 requires interaction with a second
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membrane-bound subunit, p22 phox, and in contrast with other members of the NOX family
does not require other subunits (255). NOX4 generates predominantly hydrogen peroxide (H2O2)
rather than superoxide (O2-) (256,257), although it is able to generate superoxide under specific
conditions.
Because of the increasing interest in the potential role of ROS in fibrogenic processes in a
variety of tissues and the realization that NOX family members are key effectors, substantial
efforts are now being devoted to develop selective NOX inhibitors. The first of these to be
obtained are the triazolo pyrimidines such as VAS2870 and VAS3947, which inhibit NOX
specifically but are not isotype selective (258). These compounds have been shown to be
effective in vitro in several cell systems expressing different NOX isotypes. However, because of
the lack of isotype specificity, intense efforts have been devoted to the development of NOX4specific or selective inhibitors (259). To date the best of these are pyrazolopyridine dione
derivatives, the most potent of which is GKT136901. This and similar compounds demonstrated
good oral bioavailability and safety profiles as well as dual inhibitory activity for NOX4 and
NOX1 in the nanomolar range and have been shown to inhibit EMT and prevent bleomycininduced pulmonary fibrosis. These findings suggest that the best pyrazolopyridine dione
derivatives warrant clinical trials for treatment of IPF and other fibrotic disorders.

Matrix Stiffness and Fibrogenesis. Recent studies have convincingly demonstrated that the
mechanical properties of the ECM can modulate the behavior of resident cells including
regulation of their proliferation, biosynthetic activities and stage of differentiation, although the
molecular mechanisms mediating these activities are only beginning to be understood. When
lung fibroblasts were cutured on polyacrylamide substrates of varying stiffness, they responded
by producing increasing amounts of polymerized α-SMA (260,261). This actin polymerization
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resulted in nuclear translocation of MKL1, a cofactor that plays a central role in expression of
fibrotic genes including α-SMA. Furthermore matrix stiffening promoted production and
activation of RhoA, increased ROCK activity and enhanced fibroblast contractility. Inhibition of
RhoA/ROCK blocked these responses including MKL1 nuclear translocation and myofibroblast
differentiation. Similar results were obtained with hepatic stellate cells which became
progressively myofibroblastic with increasing substrate stiffness (262).

These experiments suggest that as fibrogenesis proceeds and tissues become increasingly
stiff, a vicious cycle can be initiated in which the stiffness itself can promote further ECM
production. Furthermore, these findings suggest that therapeutic approaches aimed at the
reduction of tissue stiffness may prove to be extremely potent antifibrotic agents. As discussed
above, RhoA/ROCK inhibitors including statins are already available and may be more generally
useful as anti-fibrotic drugs than currently understood. A substantial portion of ECM stiffness
can be attributed to the crosslinking of collagen mediated by the copper-requiring enzyme lysyl
oxidase, rendering controlled inhibition of lysyl oxidase a potential therapeutic approach. In this
regard it should also be pointed out that the drug d-penicillamine, which was extensively utilized
as an antifibrotic agent in the past (263-266) but was discredited following a high dose versus
low dose comparative study (267), is a potent inhibitor of collagen crosslinking and may,
therefore, be extremely effective in reducing tissue stiffness. These considerations should lead to
the re-evaluation of d-penicillamine as an antifibrotic agent. Another potential approach to the
fibrotic stiffness problem in carefully selected cases is the direct injection of clostridial
collagenase into the affected tissue. This technique has been used successfully in nonsurgical
treatment of Dupuytren’s contracture (268).
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Inhibition of Fibrosis by an Endostatin-1 Derived peptide. A recent novel and potentially
ground-breaking study has shown that a cell-permeable peptide corresponding to the carboxy
terminal end of the endostatin-1 molecule is capable of exerting remarkable effects on the pattern
of gene expression of human normal fibroblasts in culture (269). The peptide caused a potent
antifibrotic effect modulating several aspects of fibroblast biology including a decrease in
expression of the important profibrotic transcription factor EGR-1, reduction of the expression of
type I collagen and fibronectin, and inhibition of the expression of lysyl oxidase, the main
collagen crosslinking enzyme. This study opens up the possibility of utilizing cell-permeable
peptides for the treatment of SSc, IPF, and other fibrotic diseases.

Discussion and Conclusions
The present challenges facing the field of fibrotic diseases in terms of therapy bear some
similarities to the approach for cancer treatment. The treating physicians are confronted with
complex pathogenetic processes which, although similar in their final outcome, are quite diverse
in specific molecular mechanisms. Thus, identifying critical targets and appropriate, effective
therapies is extremely difficult. Owing to the diversity and heterogeneity of the fibrotic diseases
with respect to their etiology and pathogenesis, novel screening approaches will be required to
characterize and identify particular pathways operative in individual cases. Substantial progress
in this direction has been made in the cancer field, mainly due to the availability of large data
bases documenting genetic alterations in malignant cells. While this approach has at best a
limited place in fibrotic disease, RNA microarray screening of samples derived from affected
tissues is feasible and is currently being implemented. Such analyses have been carried out
comparing samples from fibrotic tissue from SSc and IPF patients and control tissues in which
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substantial differences were observed between the normal and fibrotic samples. However, based
upon this kind of data it has not been possible, as yet, to develop pathogenetic models which
could lead to rational therapeutic approaches. As detailed in the text, there has been an explosive
growth in new findings documenting alterations in potentially profibrotic growth
factors/cytokines and in their signaling pathways. The challenge is how to apply these findings in
individual cases. Presently, the only way to determine such changes is by invasive biopsies and
even then sophisticated screening and molecular analyses of the samples would be difficult at
best or marginally informative. Thus, there is an urgent need for the identification of novel
biomarkers, most desirably from serum or plasma samples, which have the power to categorize
fibrotic reactions with respect to the active pathogenetic mechanisms and pathways.
A second major difficulty is the lack of suitable surrogate parameters capable of
measuring the effectiveness of novel therapeutic agents. As listed in Table I (and this list is by no
means complete) there is a plethora of drugs which are attractive candidates based largely on in
vitro evidence from laboratory studies and supportive animal experimental findings, although
they have not been appropriately tested in controlled clinical studies. Constructing well designed
controlled clinical trials will be a difficult although a quite necessary step that will require the
cooperation of multiple investigators and centers using both non-invasive and invasive
measurements as discussed recently for SSc clinical trials (270). On the positive side, many
existing drugs have been approved for other purposes (e.g. imatinib, rosiglitozone) eliminating
the necessity for extensive safety testing. Another feature that is now becoming apparent and that
fibrotic diseases share with cancer is the necessity of using multiple drugs to affect different
pathways. This is due to the fact that the pathogenetic mechanisms of fibrotic diseases consist of
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complex networks of multiple and often redundant pathways and blocking a single node, while
occasionally effective, will usually not be sufficient or effective.
However, it is expected that in the near future translational medicine will be able to
successfully overcome these serious challenges and convert the extensive knowledge acquired
recently about the cellular and molecular mechanisms of tissue fibrosis into effective therapeutic
approaches for the devastating and currently incurable fibrotic diseases.
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FIGURE LEGENDS
Figure 1. Cellular origins and pathways leading to activated myofibroblasts. Insults caused
by a variety of putative causative agents such as bacteria, toxins, ROS, or radiation in genetically
predisposed hosts result in inflammation. Activated inflammatory cells secrete cytokines and
growth factors such as TGF-β which cause fibroblast activation and differentiation of endothelial
and epithelial cells into myofibroblasts. These cells produce excess amounts of ECM resulting in
dysfunctional fibrotic tissue.
Figure 2. TGF-β signaling pathways critical for the fibrotic response. Illustrated are
canonical and non-canonical pathways originating from two representative dimeric receptors.
Following TGF-β binding, the TGFβRll receptor recruits a TGFβRl, either activin-like kinase-1
or activin-like kinase-5 and activates it by phosphorylaton. Activin-like kinase 5 (Alk 5) then
specifically phosphorylates receptor-regulated Smad2 and Smad3 which then complex with CoSmad4 resulting in their transport to the nucleus where they interact with various co-activators or
co-repressors to regulate transcription of critical genes, here represented by connective tissue
growth factor (CTGF) and α1(l) and α2(1) collagen genes. Also illustrated are several noncanonical pathways. An important one involves the phosphorylation and activation of the cellular
Abelson non-receptor kinase (c-Abl) resulting in activation of several downstream critical factors
including Smad1, early growth response protein (EgR) and protein kinase C delta (PKC-δ), all of
which contribute to the fibrotic response.

Figure 3. Growth factor/cytokine signaling pathways important in fibrogenesis. Illustrated
are the signaling pathways for platelet derived growth factor (PDGF), Notch, Wnt and
Hedgehog. Each of these pathways is activated by ligand-binding to specific receptors, but the
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subsequent signaling transmission mechanisms between these pathways differ dramatically (see
text). For clarity of presentation they have been abbreviated with only the essential features
presented.

39

TABLE 1. ANTI-FIBROTIC THERAPEUTIC TARGETS AND PHARMACOLOGIC
AGENTS

Target

Agent

TGF-β expression and activation

pirfenidone
αvβ6 antibody
ATI and ATII receptor blockers
ACE inhibitors
CAT-192 (anti-TGF-β1 monoclonal AB)
Caveolin scaffolding domain (CSD)

TGF-β Signaling pathways
Canonical
TBR1
SMAD3

SM305
SIS3

Non-canonical
c-Abl
PDGFR
c-kit
PKC-δ

imatinib mesylate
dasatinib
nilotinib
small specific polypeptide
rottlerin derivatives

CTGF

monoclonal CTGF antibodies

Inhibition of fibrocyte homing
CXCL12
CXCR4
CCR2

antibody
AMD3100 and others
inhibitors (PF-04136309)

src

dasatinib, SU6656

VEGFR

nintedanib (BIBF1120)

FGFR

sorafenib

Other intracellular pathways
JAK2
Wnt
Hedgehog
Notch

TG 101209
Dkk-1
LDE223
DAPT
40

RhoA

statins,
GGT inhibitor
Y27632, fasudil
caveolin scaffolding domain (CSD)
CC-930

ROCK
MEK, ERK,JNK, Akt,
JNK
Transcription factors
AP-1
Fli-1
Sp1
PPARγ

T-5524
macrolide antibiotics
intercalating agents
rosiglitazone

Other mechanisms
IL-13
IL-6 receptor
TLR
Nox4 (ROS)
ET-1
Matrix stiffness, collagen crosslinking

humanized monoclonal AB
Tocilizumab
TLR inhibitors (E5564, TAK-242)
GKT136901
Bosentan, other ET receptor blockers
d-penicillamine, Clostridial collagenase
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